Schedule 13D ownership disclosure

Aligos Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 01626L204

Event date: 2025-03-10

Filing-level shares
175,509
Percent of class
3.2%
  • Lawrence M. Blatt, Ph.D.Reported CIK 0001242110

    Shares: 175,509 · Class: 3.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-038262
Form type
SCHEDULE 13D/A
Filer
Aligos Therapeutics, Inc.
CIK
CIK 1799448
Filed
Mar 12, 2025
Reporting period
Mar 10, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub